Steven D. Reich

Artelo Enters Next Phase Of Evaluation Of Its Cannabinoid Receptor Targeting Drug For The Treatment Of Cancer-Related Anorexia And Weight Loss

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, has initiated the phase 2a p